Bevacizumab in elderly patients with metastatic colorectal cancer

Journal of Geriatric Oncology

Volumn 5, Issue 1, 2014, Pages 78-88

  Sclafani, Francesco ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bevacizumab; Colorectal cancer; Elderly

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

ARTERIAL THROMBOEMBOLISM; BLEEDING; BRAIN ISCHEMIA; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FISTULA; GERIATRIC DISORDER; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

BEVACIZUMAB; COLORECTAL CANCER; ELDERLY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; EPIDEMIOLOGIC METHODS; HUMANS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84893682324     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.08.006     Document Type: Review

References (42)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. American Cancer Society Cancer Facts & Figures http://www.cancer.org/.
3. Edwards B.K., Howe H.L., Ries L.A., Thun M.J., Rosenberg H.M., Yancik R., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94:2766-2792.
4. Cancer Research UK http://www.cancerresearchuk.org/cancer-info/cancerstats/.
5. Minino A.M., Murphy S.L. Death in the United States, 2010. NCHS Data Brief 2012, 99:1-8.
6. Minino A.M., Murphy S.L., Xu J., Kochanek K.D. Deaths: final data for 2008. Natl Vital Stat Rep 2011, 59:1-126.
7. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65years of age or older in cancer clinical trials. J Clin Oncol 2003, 21:1383-1389.
8. Folprecht G., Cunningham D., Ross P., Glimelius B., Di Costanzo F., Wils J., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004, 15:1330-1338.
9. Goldberg R.M., Tabah-Fisch I., Bleiberg H., de Gramont A., Tournigand C., Andre T., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24:4085-4091.
10. Folprecht G., Seymour M.T., Saltz L., Douillard J.Y., Hecker H., Stephens R.J., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2691 patients in randomized controlled trials. J Clin Oncol 2008, 26:1443-1451.
11. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
12. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
13. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial cell growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
14. Kabbinavar F.F., Hurwitz H., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
15. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht J.R., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
16. Rougier P., Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996, 23:34-41.
17. Rougier P., Bugat R., Douillard J.Y., Culine S., Suc E., Brunet P., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251-260.
18. Rothenberg M.L., Cox J.V., DeVore R.F., Hainsworth J.D., Pazdur R., Rivkin S.E., et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999, 85:786-795.
19. Tebbutt N.C., Wilson K., Gebski V.J., Cummins M.M., Zannino D., van Hagel G.A., et al. Capecitabine, bevacizumab and mitomycin C in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomised phase III MAX study. J Clin Oncol 2010, 28:3191-3198.
20. Price T.J., Zannino D., Wilson K., Simes R.J., Cassidy J., Van Hazel G.A., et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol 2012, 23:1531-1536.
21. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
22. Venderbosch S., Doornebal J., Teerenstra S., Lemmens W., Punt C.J.A., Koopman M. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol 2012, 51:831-839.
23. Quipourt V., Jooste V., Cottet V., Faivre J., Bouvier A.M. Co-morbidities alone do not explain the under treatment of colorectal cancer in older patients: a French population base study. J Am Geriatr Soc 2011, 59:694-698.
24. Kabbinavar F.F., Hurwitz H.I., Yi J., Sarkar S., Rosen O. Addition of bevacizumab to fluorouracil-based first line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2008, 27:199-205.
25. Cassidy J., Saltz L.B., Giantonio B.J., Kabbinavar F.F., Hurwitz H.I., Rohr U.P. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010, 136:737-743.
26. Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
27. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
28. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
29. Kozloff M.F., Yood M.U., Berlin J., Flynn P.J., Kabbinavar F.F., Purdie D.M., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14:862-870.
30. Kozloff M.F., Berlin J., Flynn P.J., Kabbinavar F., Ashby M., Dong W., et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78:329-339.
31. Kozloff M., Bekaii-Saab T.S., Bendell J.C., Cohn A.L., Hurwitz H., Roach N., et al. Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). J Clin Oncol 2011, 29. [Suppl.; abstr 3625].
32. Bendell J.C., Bekaii-Saab T.S., Cohn A.L., Hurwitz H.I., Kozloff M., Tezcan H., et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012, 17:1486-1495.
33. Kubala E., Bartos J., Petruzelka L.B., Prausova J., Benesova V., Gruna J., et al. Safety and effectiveness of bevacizumab in combination with chemotherapy in elderly patients with metastatic colorectal cancer: results from a large Czech observational registry. Proc Am Soc Clin Oncol Gastrointest Cancer Symp 2010, abstract 467.
34. Smith D., Rouyer M., Noize P., Lassalle R., Bernard O., Burki F., et al. Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: results of ETNA, a French cohort study. J Clin Oncol 2011, 29. [Suppl. 4; abstr 555].
35. Meyerhardt J.A., Li L., Sanoff H.K., Carpenter W., Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012, 30:608-615.
36. Cunningham D., Lang I., Lorusso V., Ocvirk J., Shin D., Jonker D.J., et al. Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): results of a randomized international phase III trial (AVEX). J Clin Oncol 2012, 30. [Suppl. 34; abstr 337].
37. ClinicalTrials.gov Identifier: NCT01024504. http://clinicaltrials.gov/.
38. ClinicalTrials.gov Identifier: NCT00120172. http://clinicaltrials.gov/.
39. ClinicalTrials.gov Identifier: NCT01067053. http://clinicaltrials.gov/.
40. ClinicalTrials.gov Identifier: NCT00569699. http://clinicaltrials.gov/.
41. ClinicalTrials.gov Identifier: NCT01279681. http://clinicaltrials.gov/.
42. ClinicalTrials.gov Identifier: NCT01417494. http://clinicaltrials.gov/.